Global Insulin API Market Insights and Forecast to 2027

Insulin is used to treat type 1 diabetes (condition in which the body does not produce insulin and therefore cannot control the amount of sugar in the blood). It is also used to treat people with type 2 diabetes (condition in which the body does not use insulin normally and, therefore, cannot control the amount of sugar in blood) who need insulin to control their diabetes. Nowadays, Insulin as an important drug is widely used to treat diabetes.
In China and Chinese insulin market, animal insulin, called first generation insulin, has been almost replaced by new type generation insulin. Basing on the trend of China and Chinese insulin industry, this report researches the market of human insulin and insulin analogue in China.
In this report, the statistics of insulin industry is based on Insulin API, the physical features of insulin API is Freeze-dried powder. The weight unite of insulin API weight is Kg in this report.
The main production are concentrated in Novo Nordisk, Eli Lilly, Sanofi. Gan Lee Tonghua Dongbao in recent years to expand production capacity, and they are the main providers of insulin API.
Insulin API is widely used in Fast-acting, Intermediate-acting and Long-acting Product. The most proportion of Insulin API is used in Long-acting, and the proportion in 2019 is about 41%.

Market Analysis and Insights: Global Insulin API Market
The global Insulin API market is valued at US$ 1664.2 million in 2019. The market size will reach US$ 2013.8 million by the end of 2026, growing at a CAGR of 2.9% during 2021-2026.

Global Insulin API Scope and Market Size
Insulin API market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Insulin API market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2016-2027.

Segment by Type
Regular Human Insulin
Insulin Analogue

Segment by Application
Fast-Acting
Premix
Long-Acting

By Company
Novo Nordisk
Sanofi-Aventis
Eli Lilly
Tonghua Dongbao
Ganlee
United Laboratory
Biocon
Amphastar
Wockhardt
Julphar Diabetes
Torrent Pharma

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia

Frequently Asked Questions